Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1776-260X

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC ; volume:16 ; number:5 ; day:26 ; month:9 ; year:2021 ; pages:687-695 ; date:9.2021
Targeted oncology ; 16, Heft 5 (26.9.2021), 687-695, 9.2021

Creator: Lamb, Yvette N.

Contributor: SpringerLink (Online service)

DOI: 10.1007/s11523-021-00839-w

URN: urn:nbn:de:101:1-2022010519044846793010

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:30 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Lamb, Yvette N.
SpringerLink (Online service)

Other Objects (12)

Correction to: Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC

Osimertinib : Therapieplanung und Therapiesequenzen beim fortgeschrittenen EGFR-mutierten NSCLC

Osimertinib and palbociclib in an EGFR-mutated NSCLC with primary CDK4 amplification after progression under osimertinib

Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC

Osimertinib for Previously Treated Patients With Advanced EGFR T790M Mutation-Positive NSCLC: Tolerability and Diagnostic Methods From an Expanded Access Program

Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases

Treatment Patterns and Resource Use After Osimertinib Discontinuation in Patients with EGFR + Metastatic NSCLC

Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIs

Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study

Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines

Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib

Osimertinib (NSCLC, adjuvant) : Nutzenbewertung gemäß § 35a SGB V

Correction to: Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC

Osimertinib : Therapieplanung und Therapiesequenzen beim fortgeschrittenen EGFR-mutierten NSCLC

Osimertinib and palbociclib in an EGFR-mutated NSCLC with primary CDK4 amplification after progression under osimertinib

Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC

Osimertinib for Previously Treated Patients With Advanced EGFR T790M Mutation-Positive NSCLC: Tolerability and Diagnostic Methods From an Expanded Access Program

Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases

Treatment Patterns and Resource Use After Osimertinib Discontinuation in Patients with EGFR + Metastatic NSCLC

Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIs

Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study

Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines

Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib

Osimertinib (NSCLC, adjuvant) : Nutzenbewertung gemäß § 35a SGB V

Correction to: Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC

Osimertinib : Therapieplanung und Therapiesequenzen beim fortgeschrittenen EGFR-mutierten NSCLC

Osimertinib and palbociclib in an EGFR-mutated NSCLC with primary CDK4 amplification after progression under osimertinib

Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC

Osimertinib for Previously Treated Patients With Advanced EGFR T790M Mutation-Positive NSCLC: Tolerability and Diagnostic Methods From an Expanded Access Program

Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases

Treatment Patterns and Resource Use After Osimertinib Discontinuation in Patients with EGFR + Metastatic NSCLC

Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIs

Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study

Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines

Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib

Osimertinib (NSCLC, adjuvant) : Nutzenbewertung gemäß § 35a SGB V

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read and agree to the privacy policy for the collection of personal data.*

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC

Show object

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Correction to: Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC

Osimertinib : Therapieplanung und Therapiesequenzen beim fortgeschrittenen EGFR-mutierten NSCLC

Osimertinib and palbociclib in an EGFR-mutated NSCLC with primary CDK4 amplification after progression under osimertinib

Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC

Osimertinib for Previously Treated Patients With Advanced EGFR T790M Mutation-Positive NSCLC: Tolerability and Diagnostic Methods From an Expanded Access Program

Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases

Treatment Patterns and Resource Use After Osimertinib Discontinuation in Patients with EGFR + Metastatic NSCLC

Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIs

Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study

Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines

Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib

Osimertinib (NSCLC, adjuvant) : Nutzenbewertung gemäß § 35a SGB V

Correction to: Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC

Osimertinib : Therapieplanung und Therapiesequenzen beim fortgeschrittenen EGFR-mutierten NSCLC

Osimertinib and palbociclib in an EGFR-mutated NSCLC with primary CDK4 amplification after progression under osimertinib

Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC

Osimertinib for Previously Treated Patients With Advanced EGFR T790M Mutation-Positive NSCLC: Tolerability and Diagnostic Methods From an Expanded Access Program

Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases

Treatment Patterns and Resource Use After Osimertinib Discontinuation in Patients with EGFR + Metastatic NSCLC

Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIs

Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study

Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines

Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib

Osimertinib (NSCLC, adjuvant) : Nutzenbewertung gemäß § 35a SGB V

Correction to: Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC

Osimertinib : Therapieplanung und Therapiesequenzen beim fortgeschrittenen EGFR-mutierten NSCLC

Osimertinib and palbociclib in an EGFR-mutated NSCLC with primary CDK4 amplification after progression under osimertinib

Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC

Osimertinib for Previously Treated Patients With Advanced EGFR T790M Mutation-Positive NSCLC: Tolerability and Diagnostic Methods From an Expanded Access Program

Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases

Treatment Patterns and Resource Use After Osimertinib Discontinuation in Patients with EGFR + Metastatic NSCLC

Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIs

Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study

Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines

Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib

Osimertinib (NSCLC, adjuvant) : Nutzenbewertung gemäß § 35a SGB V

Related objects

Reset password